Lightlake Therapeutics (LLTP) 0.0360 $LLTP
Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
PR Newswire - Wed Jul 23, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND" with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.
Lightlake Therapeutics Inc. Signs Agreement With Commercial Contract Manufacturer For Its Opioid Overdose Reversal Treatment
PR Newswire - Wed Jul 09, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production facilities to enable commercialization of its treatment on a global scale.
Bulimia Nervosa Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t543w6/bulimia_nervosa) has announced the addition of the "Bulimia Nervosa Global Clinical Trials Review, H1, 2014" report to their offering. "Bulimia Nervosa Global Clinical Trials Review, H1, 2014" provides data on the Bulimia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bulimia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bulimia Nervosa. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Lightlake Therapeutics Inc. - Interapy PLC Clinical Trial Overview of Top Institutes / Government - New York State Psychiatric Institute - The University of North Carolina - National Institute of Mental Health - Kaiser Permanente - The National Institute of Diabetes and Digestive and Kidney Diseases - Lindner Center of HOPE - Neuropsychiatric Research Institute - Ministry of Education and Research, Germany - Medical University of Vienna - University of Michigan For more information visit http://www.researchandmarkets.com/research/t5...ia_nervosa
Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
PR Newswire - Fri Dec 20, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013.
OTC Signal Daily Stock Watch - Lightlake Therapeutics Inc., (OTCQB: LLTP)
WorldStockWire - Tue Sep 03, 8:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Lightlake Therapeutics Announces Partnership with National Institute on Drug Abuse (NIDA) to Treat Opioid Overdose
PR Newswire - Wed Aug 21, 7:30AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today the Company is moving forward in expanding access to medication for the treatment of opioid overdose with the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" . This fall, NIDA will sponsor a two-week clinical study designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.
Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
PR Newswire - Mon Aug 05, 8:00AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA" , a leading New York-based communications firm, to direct the Company's investor and public relations programs.
Lightlake Therapeutics Inc. to Present at 4th Annual OneMedForumNY 2013
Business Wire - Tue Jun 18, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be participating in the 4th Annual OneMedForum New York taking place June 26th and June 27th, 2013 at The Metropolitan Club in New York City. Dr. Roger Crystal, Chief Executive Officer of Lightlake, is scheduled to present an update on the Company's corporate and clinical developments on Thursday, June 27th at 12:20 p.m. EDT.
Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
Business Wire - Thu May 23, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder ("BED" were presented at the American Psychiatric Association ("APA" Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
Lightlake Therapeutics Inc. to Develop Opioid Drug Treatment in Collaboration with the National Institute on Drug Abuse (NIDA)
Business Wire - Wed Apr 24, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse ("DPMCDA" of the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to co-develop a treatment for opioid addiction that utilizes the Company's innovative proprietary technology.
Lightlake Therapeutics Inc. Provides Guidance on Company Operations
Business Wire - Thu Apr 04, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , an early stage biopharmaceutical company developing addiction treatments, announced today the clinical progress and corporate developments the Company has achieved during the last six months, and provided insights on its plans to develop opioid drug addiction treatments.
Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
Business Wire - Wed Mar 27, 5:30AM CDT
Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the "Company" or "Lightlake" , an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.
Addiction - Pipeline Review: Latest updates and review of key players
M2 - Wed Jan 09, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2xs3/addiction) has announced the addition of Global Markets Direct's new report "Addiction - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Addiction. - A review of the Addiction products under development by companies and universities/research institutes based on information derived from com
Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
PR Newswire - Wed Jul 23, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND" with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013. Lightlake Therapeutics Inc. Signs Agreement With Commercial Contract Manufacturer For Its Opioid Overdose Reversal Treatment
PR Newswire - Wed Jul 09, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production facilities to enable commercialization of its treatment on a global scale. Bulimia Nervosa Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t543w6/bulimia_nervosa) has announced the addition of the "Bulimia Nervosa Global Clinical Trials Review, H1, 2014" report to their offering. "Bulimia Nervosa Global Clinical Trials Review, H1, 2014" provides data on the Bulimia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bulimia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bulimia Nervosa. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Lightlake Therapeutics Inc. - Interapy PLC Clinical Trial Overview of Top Institutes / Government - New York State Psychiatric Institute - The University of North Carolina - National Institute of Mental Health - Kaiser Permanente - The National Institute of Diabetes and Digestive and Kidney Diseases - Lindner Center of HOPE - Neuropsychiatric Research Institute - Ministry of Education and Research, Germany - Medical University of Vienna - University of Michigan For more information visit http://www.researchandmarkets.com/research/t5...ia_nervosa
Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
PR Newswire - Fri Dec 20, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" or the "Company"
(OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013. OTC Signal Daily Stock Watch - Lightlake Therapeutics Inc., (OTCQB: LLTP)
WorldStockWire - Tue Sep 03, 8:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Lightlake Therapeutics Announces Partnership with National Institute on Drug Abuse (NIDA) to Treat Opioid Overdose
PR Newswire - Wed Aug 21, 7:30AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company"
(OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today the Company is moving forward in expanding access to medication for the treatment of opioid overdose with the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" . This fall, NIDA will sponsor a two-week clinical study designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
PR Newswire - Mon Aug 05, 8:00AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company"
(OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA" , a leading New York-based communications firm, to direct the Company's investor and public relations programs. Lightlake Therapeutics Inc. to Present at 4th Annual OneMedForumNY 2013
Business Wire - Tue Jun 18, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"
, a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be participating in the 4th Annual OneMedForum New York taking place June 26th and June 27th, 2013 at The Metropolitan Club in New York City. Dr. Roger Crystal, Chief Executive Officer of Lightlake, is scheduled to present an update on the Company's corporate and clinical developments on Thursday, June 27th at 12:20 p.m. EDT. Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
Business Wire - Thu May 23, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"
, a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder ("BED" were presented at the American Psychiatric Association ("APA" Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial. Lightlake Therapeutics Inc. to Develop Opioid Drug Treatment in Collaboration with the National Institute on Drug Abuse (NIDA)
Business Wire - Wed Apr 24, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"
, a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse ("DPMCDA" of the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to co-develop a treatment for opioid addiction that utilizes the Company's innovative proprietary technology. Lightlake Therapeutics Inc. Provides Guidance on Company Operations
Business Wire - Thu Apr 04, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"
, an early stage biopharmaceutical company developing addiction treatments, announced today the clinical progress and corporate developments the Company has achieved during the last six months, and provided insights on its plans to develop opioid drug addiction treatments. Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
Business Wire - Wed Mar 27, 5:30AM CDT
Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the "Company" or "Lightlake"
, an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013. Addiction - Pipeline Review: Latest updates and review of key players
M2 - Wed Jan 09, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2xs3/addiction) has announced the addition of Global Markets Direct's new report "Addiction - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Addiction. - A review of the Addiction products under development by companies and universities/research institutes based on information derived from com
